000136951 001__ 136951
000136951 005__ 20240229105108.0
000136951 0247_ $$2doi$$a10.1002/chir.22982
000136951 0247_ $$2pmid$$apmid:29978505
000136951 0247_ $$2ISSN$$a0899-0042
000136951 0247_ $$2ISSN$$a1520-636X
000136951 037__ $$aDKFZ-2018-01380
000136951 041__ $$aeng
000136951 082__ $$a570
000136951 1001_ $$0P:(DE-He78)c53db83479d3d1265967405af71f69bb$$aKlika, Karel$$b0$$eFirst author$$udkfz
000136951 245__ $$aInternal chirality descriptors iR and iS and ire and isi. A proposed notation to extend the usefulness of the R/S system by retaining the sense of stereochemistry in cases of ligand ranking changes.
000136951 260__ $$aNew York, NY [u.a.]$$bWiley Interscience$$c2018
000136951 3367_ $$2DRIVER$$aarticle
000136951 3367_ $$2DataCite$$aOutput Types/Journal article
000136951 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536663268_12888
000136951 3367_ $$2BibTeX$$aARTICLE
000136951 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136951 3367_ $$00$$2EndNote$$aJournal Article
000136951 520__ $$aThe R/S system, universally applied for indicating the absolute configuration of a structure, is extremely adept for conveying the absolute configuration unequivocally. However, it suffers from one limitation, viz that due to CIP priority rules the rankings of the ligands attached to an asymmetric center can be altered upon a change in a ligand leading to a change in the designated configuration even if bonds to the asymmetric center were not actually formed or broken. This means that the sense of stereochemistry in situations such as within a set of compounds where family relationships are of focus or where the sense of the stereochemical course of a reaction is of interest can be lost or confusion may occur. This shortcoming is easily remedied though by defining a fixed ranking for a particular ligand in the system under study, eg, the ligand at which the change has occurred. The configurations are then expressed as iR or iS, akin to the R and S descriptors, for sp3 -hybridized tetrahedral chiral structures and similarly, as ire and isi faces, akin to the re and si descriptors, for sp2 -hybridized trigonal prochiral structures. All in all, the notation can be considered as an auxiliary to extend the usefulness of the R/S system. Thus, the proposed iR/iS notation could find profitable use in comparative studies where there is a need to avoid confusion arising from changing assignments due to priority rules or to expedite the ease of comprehension. Moreover, in the current digital age, the facile retrieval of stereochemically clear data by machines is highly desirable-something that the iR/iS notation is readily amenable to.
000136951 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000136951 588__ $$aDataset connected to CrossRef, PubMed,
000136951 7001_ $$00000-0001-9041-7034$$aWzorek, Alicja$$b1
000136951 7001_ $$00000-0003-0681-4526$$aSoloshonok, Vadim A$$b2
000136951 773__ $$0PERI:(DE-600)2001237-8$$a10.1002/chir.22982$$gVol. 30, no. 9, p. 1054 - 1066$$n9$$p1054 - 1066$$tChirality$$v30$$x0899-0042$$y2018
000136951 909CO $$ooai:inrepo02.dkfz.de:136951$$pVDB
000136951 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c53db83479d3d1265967405af71f69bb$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136951 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000136951 9141_ $$y2018
000136951 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136951 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136951 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136951 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCHIRALITY : 2015
000136951 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136951 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136951 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136951 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136951 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136951 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136951 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136951 9201_ $$0I:(DE-He78)G404-20160331$$kG404$$lWirkstoffforschung$$x0
000136951 980__ $$ajournal
000136951 980__ $$aVDB
000136951 980__ $$aI:(DE-He78)G404-20160331
000136951 980__ $$aUNRESTRICTED